Results 161 to 170 of about 79,526,962 (296)
Creatine kinase levels in asthma patients receiving interleukin-5 therapy. [PDF]
Kavanagh GA +4 more
europepmc +1 more source
Innate Immunocompetent hiPSC‐Derived Neurospheroids Capture Early CNS Responses to rAAV
Knowledge of human CNS immune responses to AAV‐based gene therapies remains limited due to the lack of immune‐competent human models. Here, a hiPSC‐derived 3D neuroimmune platform integrating neurospheroids and microglia is established using stirred‐tank bioreactors.
Catarina M. Gomes +14 more
wiley +1 more source
Effects of β-1.3/1.6 glucan on cytokines production by leukocytes in vitro
Sakalauskiene Jurgina +6 more
doaj +1 more source
Therapeutic Efficacy of Anti-Interleukin-5 Monoclonal Antibodies in Kimura Disease: A Systematic Review. [PDF]
Olizarowicz S +3 more
europepmc +1 more source
Interleukin-5 receptor alpha (CD125) expression on human blood and lung neutrophils. [PDF]
Lawrence MG +10 more
europepmc +1 more source
This study reveals that NF‐κB1‐driven TRAIP upregulation in ALD correlates with disease severity. Mechanistically, TRAIP directly binds β‐catenin via its CC domain and promotes its K48‐linked ubiquitination and degradation, which is independent of the GSK3β/β‐TrCP pathway.
Zhan Wu +13 more
wiley +1 more source
Pro-inflammatory and counter-regulatory modulators of interleukin-5-driven eosinophil programs: a framework for precision medicine in eosinophilic diseases. [PDF]
Sasaki H, Miyata J, Fukunaga K.
europepmc +1 more source
Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy. [PDF]
O'Reilly E +8 more
europepmc +1 more source
ABSTRACT The LRRK2 G2019S mutation, a Parkinson's disease–linked variant, has been associated with depression‐like phenotypes, but mechanisms remain unclear. We chart age‐dependent behavioral changes and astrocyte reactivity in G2019S mice and define a pathway connecting LRRK2 to TFEB/GDNF signaling, cellular energetics, and inflammation.
Longping Yao +5 more
wiley +1 more source

